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OBJECTIVE — Reduction of bone marrow–derived circulating progenitor cells has been
proposed as a novel mechanism of cardiovascular disease in type 2 diabetes. The present study
was designed to describe the extent and potential mechanisms of progenitor cell reduction
during the natural history of type 2 diabetes.
RESEARCH DESIGN AND METHODS — We identiﬁed 425 individuals, divided into
sevencategoriesaccordingtocarbohydratemetabolismstatus(normalglucosetolerance[NGT],
impaired fasting glucose, impaired glucose tolerance [IGT], and newly diagnosed type 2 diabe-
tes) and diabetes duration (0–9, 10–19, and 20 years). These categories were examined as
ideally describing the natural history of type 2 diabetes development and progression. We
measured CD34 and CD34KDR progenitor cells by ﬂow cytometry. We also evaluated
progenitor cells in 20 coupled bone marrow and peripheral blood samples and examined pro-
genitor cell apoptosis in 34 subjects.
RESULTS — In comparison to NGT, CD34 cells were signiﬁcantly reduced in IGT and had
a ﬁrst nadir in newly diagnosed type 2 diabetes and a second nadir after 20 years of diabetes.
Statistical adjustment for possible confounders conﬁrmed that CD34 cell counts are deeply
reduced at time of diagnosis, that they partially recover during the subsequent 0–19 years, and
that they dip again after 20 years. A similar, but less consistent, trend was detected for
CD34KDR cells. Peripheral blood CD34 cells were directly correlated with bone marrow
CD34 cells and inversely correlated with CD34 cell apoptosis.
CONCLUSIONS — Circulating progenitor cell reduction marks the clinical onset of type 2
diabetes. Both defective mobilization and increased apoptosis may account for this phenome-
non. While a partial recovery occurs during subsequent years, bone marrow reserve seems
exhausted in the long term.
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T
ype 2 diabetes is characterized by a
two- to fourfold increased risk of
cardiovascular disease (CVD) (1).
This is generally attributed to the adverse
effects of hyperglycemia and oxidative
stress on vascular biology (2). However,
type 2 diabetes is also associated with a
constellation of additional risk factors,
such as obesity, dyslipidemia, and hyper-
tension, which concur to promote CVD.
It has been also shown that patients with
pre-diabetic conditions, such as impaired
fasting glucose (IFG) and impaired glu-
cosetolerance(IGT),arethemselvesatin-
creased risk of CVD (3). This suggests
that abnormalities in carbohydrate me-
tabolism form a continuum that pro-
gressively worsens cardiovascular
health, but the mechanisms are not
clearly understood.
A relatively novel paradigm of CVD
pathogenesis is the loss of normal endo-
thelial turnover caused by a reduction of
circulating endothelial progenitor cells
(EPCs) (4). EPCs are mainly derived from
bone marrow and are involved in the ho-
meostasis of healthy and damaged endo-
thelium, as well as in physiologic and
compensatory angiogenesis (5). Given
their paramount role in the cardiovascu-
lar system, reduction of EPCs is believed
topromoteCVDdevelopmentorprogres-
sion (4).
EPCs are reduced in the presence of
risk factors for and of established CVD
and predict future cardiovascular events
(4,6–8). Both type 1 and type 2 diabetes
are associated with a signiﬁcant reduc-
tion of circulating EPCs (9,10), which
parallels the severity of cardiovascular
complications (11). Experimental stud-
ies suggest that the mechanisms linking
hyperglycemia to progenitor cell reduc-
tion include defective mobilization from
the bone marrow and reduced survival
(9).
We have also shown that type 2 dia-
betesandIGTareassociatedwithasignif-
icant reduction of total circulating
CD34 cells (10,12). These cells form a
more generic, immature population of
bone marrow–derived progenitors that
include EPCs and nonendothelial pro-
genitor cells potentially involved in car-
diovascular homeostasis, such smooth
muscle and cardiomyocyte progenitor
cells (13). This may have important im-
plications, as CD34 cell count is
stronglycorrelatedwithallcardiovascular
parametersandriskestimates(6)andpre-
dicts cardiovascular outcomes in patients
with metabolic disorders (14). However,
it is not clear to what extent progenitor
cell defects in type 2 diabetic patients are
related to diabetes, per se, or to the asso-
ciated cardiovascular risk factors. More-
over, in order prevent or treat diabetes
complications, an increasing number of
drugsareprescribedtothesepatientsthat
may inﬂuence progenitor cells, thus mas-
querading the relationship between dia-
betes and cell count.
The aims of this study were 1)t o
deﬁne cross-sectionally the time course
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natural history of type 2 diabetes, 2)t o
clear out possible confounders of this
relationship,and3)toidentifypotential
mechanisms of progenitor cell
reduction.
RESEARCH DESIGN AND
METHODS— An expanded descrip-
tion of materials and methods is given in
the online appendix (available at http://
care.diabetesjournals.org/cgi/content/full/
dc09-1999/DC1).
We identiﬁed 425 subjects for whom
carbohydrate metabolism state and car-
diovascular parameters were known.
They were divided into 205 subjects with
normal glucose tolerance (NGT), 40 with
IFG, 43 IGT, 32 with new-onset type 2
diabetes, 64 with 10 years long-lasting
diabetes, 20 with 10–19 years long-
lasting diabetes, and 22 with 20 years
long-lasting diabetes. CD34 and
CD34KDR cell count was performed
in all subjects. Vascular endothelial
growth factor (VEGF) concentrations
were determined in a subgroup of 98 pa-
tients. Progenitor cell apoptosis was as-
sessed in 34 patients, and bone marrow
samples were available for 20 patients.
More details on patients’ descriptions and
characterizations can be found in the on-
line appendix.
Assessment of progenitor cell count
and apoptosis
Peripheral blood and bone marrow pro-
genitorcellswerecountedbyﬂowcytom-
etry using antibodies against CD34 and
KDR, as previously described in detail by
our group (15). CD34 cells were con-
sidered generic circulating progenitors,
while CD34KDR cells were consid-
eredEPCs.ApoptosisofCD34cellswas
evaluated by costaining with Annexin V.
For more details on ﬂow cytometry see
the online appendix.
Statistical analyses
An expanded statistical section can be
found in the online appendix. Data are
expressed as means  SD, unless other-
wise speciﬁed. Progenitor cell count is al-
ways expressed as cell count per 10
6
events. To derive an estimate of progeni-
tor cell variation that was independent of
possible confounders, we used nonstand-
ardized coefﬁcients from multiple linear
regression analyses, in which each cate-
gory of patients was entered as a dichoto-
mous variable (0 or 1) compared with
NGT. To adjust data, we ﬁrst used a full
model (model 1) including all variables
listed in Table 1 (except for total choles-
terol, due to collinearity). Given the large
uncertainty of such a estimate, to select
a limited number of unrelated highly
signiﬁcant variables, we applied a step-
wise regression approach and repeated
the analyses controlling only for this
parsimonioussetofvariables(model2).
SPSS version 13.0 was used, and statis-













n 205 40 43 32 64 20 22
Age (years) 46.6  12.3 55.0  10.9* 53.0  8.5* 57.0  0.7* 65.1  11.3* 68.6  10.5* 70.4  8.6*
Male sex 98 (47.8) 28 (70.0)* 23 (53.5) 21 (65.6) 40 (62.5)* 9 (45.0) 17 (77.3)*
Plasma glucose (mg/dl) 87.5  9.0 113.9  6.5* 101.4  14.3* 142.8  41.0* 186.8  67.3* 205.8  82.6* 234.3  95.9*
A1C (%) 5.1  0.37 6.0  0.42* 5.6  0.59 7.1  0.29* 8.2  2.5* 9.6  2.2* 9.3  1.9*
BMI (kg/m
2) 24.7  4.4 27.1  3.9* 27.5  4.1* 27.6  4.5* 28.2  4.8* 29.8  6.4* 27.8  4.7*
Smoking habit 49 (23.9) 3 (7.5)* 7 (16.3) 7 (21.8) 12 (18.7) 3 (15.0) 8 (36.4)
Systolic blood pressure
(mmHg) 122.9  13.0 125.6  17.2 129.0  12.0* 141.2  17.2* 147.1  21.8* 150.5  21.1* 150.2  22.3*
Diastolic blood pressure
(mmHg) 81.6  9.7 82.6  12.1 83.6  12.1 87.1  12.3* 87.3  10.8* 83.3  11.0 81.4  10.7
Total cholesterol (mg/dl) 200.1  40.8 202.1  32.9 210.9  34.0* 190.6  37.2 179.7  44.9* 200.2  27.7 187.0  38.6
HDL cholesterol (mg/dl) 56.1  15.7 53.4  19.1 53.9  15.1 43.2  14.2* 43.6  12.7* 50.6  14.9 48.1  17.8
LDL cholesterol (mg/dl) 125.4  37.1 126.7  32.6 128.1  29.7 110.7  32.5* 105.6  40.1* 123.4  26.1 109.4  36.0*
Triglycerides (mg/dl) 97.2  54.5 110.2  67.8 144.3  66.5* 183.3  127.4* 152.4  78.2* 130.7  82.7 147.7  74.7*
Diabetic retinopathy 0 (0) 0 (0) 0 (0) 0 (0) 11 (17.2)* 9 (45.0)* 7 (31.8)*
Chronic renal failure 0 (0) 0 (0) 0 (0) 0 (0) 8 (12.5)* 7 (35)* 5 (22.7)*
CVD 14 (6.8) 2 (5.0) 2 (4.7) 6 (18.8) 39 (60.9)* 15 (75.0)* 21 (95.5)*
Medications
Statin 2  0.9 0  0.0 1  2.2 3  9.4 20  31.3* 8  40.0* 8  36.4*
ACE inhibitors/
angiotensin receptor
blockers 8  3.9 1  2.5 1  2.2 4  12.5 32  50.0* 12  60.0* 17  77.3*
Other antihypertensive 17  8.3 4  10.0 4  9.3 3  9.4 33  51.6* 12  60.0* 16  72.7*
Aspirin 0  0.00 0  0.0 1  2.2 2  6.3 13  20.3* 9  45.0* 9  41.0*
Insulin 0  0.0 0  0.0 0  0.0 0  0.0 19  29.7* 8  40.0* 14  63.6*
Oral hypoglycemic
agents 0  0.0 0  0.0 0  0.0 0  0.0 15  23.4* 11  55.0* 5  22.0.7*
Data are means  SD or n (%). Patients were divided into seven categories according to carbohydrate metabolism and duration of diabetes, as appropriate.
*Signiﬁcantly different versus NGT in least signiﬁcant difference post-ANOVA test.
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Detailed clinical characteristics of the
studypatientsarereportedinTable1.Pa-
tients were divided into seven categories
according to their degree of glucose toler-
anceorthedurationofdiabetes,asappro-
priate. Patients’ distribution in these
groups was not uniform, because about
one-halfwasclassiﬁedashavingNGT.Pa-
tients with both IFG and IGT were classi-
ﬁed as IGT. As expected, moving from
NGT to worsening categories of carbohy-
drate abnormality was associated with a
progressively worsening cardiovascular
proﬁle, while cardiovascular parameters
indiabeticpatientswerelikelyinﬂuenced
by medications. The prevalence of CVD
increased markedly with longer diabetes
duration.
Observed and adjusted CD34 cell
counts in the natural course of type
2 diabetes
We examined CD34 cell counts in sub-
jects grouped according to carbohydrate
metabolismanddiabetesduration.Circu-
lating CD34 cells were signiﬁcantly re-
ducedinsubjectswithIGT(21.9%;P
0.016 after Bonferroni correction) and
further reduced in new-onset type 2 dia-
betes in comparison with NGT (40.8%;
P  0.001). Diabetic patients with 0–19
years of disease duration still had signiﬁ-
cantly lower circulating CD34 cells
than those with NGT, but on average cell
counts were not different from that of
new-onsetdiabeticpatients.Patientswith
20 years diabetes duration had the low-
est mean cell count, which, however, was
not signiﬁcantly different from that of
new-onset diabetes and other disease du-
rations (47.9%; P  0.001 vs. NGT;
P  0.43 vs. new onset). These data indi-
cate that observed levels of circulating
CD34 cells have a ﬁrst nadir very early
in newly diagnosed type 2 diabetic pa-
tients and that a second nadir occurs at
least20yearslater(supplementalTable1)
(Fig. 1, continuous line).
We then reasoned that the observed
pattern of CD34 cell variation across
categories of carbohydrate metabolism
and diabetes duration could be inﬂu-
enced by many confounders, such as age,
concomitant risk factors, CVD, microan-
giopathy, and medications, which have
been previously shown to affect circulat-
ing progenitors (16). Therefore, we ran
multiple linear regression analyses in or-
der to correct for possible confounders
theabsoluteCD34cellvariationineach
category (supplemental Table 1). To this
end, we used two models (see STATISTICAL
ANALYSES): model 1 included all variables
listed in Table 1 and was therefore highly
redundant; model 2 included, at each
step, only variables selected by a stepwise
multiple regression procedure (IFG:
none; IGT: age; newly diagnosed diabe-
tes: plasma glucose; 0–9 years: age and
A1C; 10–19 years: age; 20 years: age
and A1C). Using both models, the trend
ofadjustedvalueswasquitesimilartothat
of observed values (supplemental Table
1) (Fig. 1A and B, dashed line). The gap
between the two curves is to be consid-
ered attributable to confounders. Bars in
the ﬁgure indicate 95% CIs of the mean
(solid lines) or 95% CI of the estimate
(dashed lines). In model 1, the uncertainty
of the estimate was very large due to the
high number of variables that were con-
trolled for. In model 2, which was pur-
Figure 1—Observed and adjusted variation of circulating CD34 cells in patients grouped
accordingtocarbohydratemetabolismordiabetes(DM)duration,asappropriate.Themeanvalue
of patients with NGT was taken to represent the zero point. Bars indicate 95% CIs of means
(observedvalues)andestimates(adjustedvalues).*Observedvaluessigniﬁcantlydifferentversus
NGT. †Adjusted values signiﬁcantly different versus NGT. Model 1 (A) and model 2 (B) refers to
the strategy used to control for confounders (see STATISTICAL ANALYSES).
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without missing highly signiﬁcant covari-
ates, bars were clearly narrower. The
trend of adjusted values conﬁrms a ﬁrst
nadir of CD34 cell count at diagnosis of
type 2 diabetes (33.8%, P  0.01 in
model 1; 31.7%, P  0.01 in model 2)
and a second nadir after 20 years of dis-
ease duration but was marginally signiﬁ-
cant (39.7% in model 1; 34.9% in
model 2).
Observed and adjusted
CD34KDR cell counts in the
natural course of type 2 diabetes
When we used the same statistical ap-
proach to analyze the time course of
CD34KDR variation in categories of
patients describing the natural history of
type 2 diabetes, we found a similar trend
as for CD34 cells, but results were less
consistent. A trend toward CD34
KDR nadir in newly diagnosed type 2
diabetes and a subsequent reduction in
longer-standing type 2 diabetes was de-
tected (Fig. 1) (supplemental Table 2).
The gap between observed and adjusted
data was larger and more inconsistent
then for CD34 cells.
Potential mechanisms of progenitor
cell reduction
Pharmacologic effects, VEGF stimulation,
cell apoptosis, and bone marrow mobiliza-
tionwereassessedaspotentialexplanations
for CD34 progenitor cell reduction.
When we examined whether the increase
and stabilization of CD34 cell count in
patients with 0–19 years diabetes duration
was related to pharmacological interven-
tions established after a diagnosis of diabe-
tes, which might inﬂuence progenitor cell
biology (such as insulin, statins, and ACE
inhibitors/angiotensin receptor blockers)
(4), we found that none of these treatments
or their combination was associated with
signiﬁcant changes in CD34 cells (Fig.
2A).
Observed plasma VEGF concentra-
tionswerereducedinpre-diabeticanddi-
abetic patients as compared with patients
with NGT, but statistical signiﬁcance was
lost after adjusting for confounders in
model 1 (Fig. 2B). We found no signiﬁ-
cant correlation between plasma VEGF
concentrations and CD34 (r  0.12;
P  0.25) or CD34KDR cells (r 
0.02; P  0.84).
In a subset of 34 subjects, we found a
signiﬁcant inverse correlation between
peripheral blood CD34 cell count and
the percentage of CD34 cell apoptosis
(Fig. 2C). In this small substudy, a trend
Figure 2—Potential mechanisms of CD34 progenitor cell reduction. A: Circulating CD34 cell counts in pooled patients with 0–19 years of
diseaseduration,dividedaccordingtotheuseofdrugsknowntoaffectperipheralbloodprogenitorcells:statins,ACEinhibitors,angiotensinreceptor
blockers (ARBs), insulin, and all these medications together. B: Variation of plasma VEGF concentrations in pre-diabetic (IFG/IGT) and diabetic
(DM)versussubjectswithNGT.*SigniﬁcantversusobservedNGTvalues.C:Asigniﬁcantnegativecorrelationwasfoundbetweenperipheralblood
CD34 cell count and the apoptotic rate of CD34 cells. D: A signiﬁcant direct correlation was found between peripheral blood and bone marrow
CD34 cell counts. F, nondiabetic subjects; E, diabetic patients; Ctrl, control.
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diabetes versus NGT was conﬁrmed
(361  36 vs. 497  60; P  0.07), but
theapoptoticratewasnotdifferent(4.9
1.3% vs. 5.0  0.7%; P  0.92).
In a sample of 10 nondiabetic and 10
diabetic subjects CD34 cells were mea-
sured in both peripheral blood and bone
marrow. We found a direct correlation be-
tween cell counts in the two compartments
(Fig. 2D). CD34 cells were lower in dia-
betic than in nondiabetic patients in both
peripheral blood (290  24 vs. 388  57;
P  0.13) and bone marrow (2,061  183
vs. 4,026  640; P  0.008).
CONCLUSIONS — The present study
was designed to describe the trend of pro-
genitor cell decline during the natural his-
toryoftype2diabetes.Sincedecadeswould
be needed to address this issue prospec-
tively, we cross-sectionally examined pa-
tients at different stages of disease
developmentandprogression,providingan
overview that simulates a longitudinal per-
spective. The interest in better deﬁning the
relationships between progenitor cells and
diabetes stands in the notion that progeni-
tor cells are involved in cardiovascular
homeostasis, and their reduction indepen-
dently predicts cardiovascular events (14).
In the present study, unadjusted data indi-
cate that the level of circulating CD34
cells starts to decline very early in the natu-
ral course of type 2 diabetes, having a ﬁrst
nadir at the time of diagnosis. Surprisingly,
patientswith0–19yearsofdiabetesdidnot
show a further progressive decline in pro-
genitor cell count, as it would be straight-
forwardly expected from a time-dependent
cumulative damage model (17). Rather, in
this category of patients, CD34cell count
provedtobeslightlyincreasedorstabilized.
Only after at least 20 years of disease dura-
tion,therewasasecondnadirofcirculating
CD34 cells. This trend was likely inﬂu-
enced by many confounders. First, there
was an almost linear increase in age across
categoriesofpatients,andagingisknownto
progressively restrict bone marrow reserve
andreducecirculatingprogenitorcelllevels
(6,18).Additionally,withworseningcarbo-
hydrate metabolism, concomitant abnor-
malities became more prevalent, including
overweight, dyslipidemia, and hyperten-
sion, all of which have been previously as-
sociatedwithprogenitorcelldecline(6,19).
Moreover,highglucoseatthetimeofblood
sampling may have inﬂuenced progenitor
cell count, per se, as known from in vivo
and in vitro observations (10,20). The
higher prevalence of CVD in patients with
longer disease duration may have con-
foundedtherelationshipbetweencellcount
and diabetes, because CVD patients usually
have lower levels of circulating progenitor
cells (6). Finally, patients were prescribed
with different classes of drugs, such as st-
atins, ACE inhibitors, and insulin, all of
which have the potential to modulate pro-
genitor cells (4,21,22). To remove these
confounders, we used two multiple linear
regressionmodels,andthevariationofpro-
genitor cell count attributable only to pa-
tients’ category was estimated from
regression coefﬁcients. Model 1 was pur-
portedlyredundant,asitincludedallpossi-
ble confounding variables, but led to a high
uncertainty in the estimate of cell count re-
duction. Conversely, model 2 was highly
conservative, as it included only variables
selected by a preliminary stepwise analysis,
thus producing narrower CIs of the esti-
mate. Both models revealed a trend of pro-
genitor cell count that was quite similar to
observed data (supplemental Table 1). The
gapbetweenthetwocurvesinFig.1istobe
considered attributable to confounders and
vary according to the model used. Both
analysesindicatethatobservedCD34cell
reductioninthesepatientsispartlyattribut-
able to aging, concomitant risk factors, or
CVD and not entirely to their carbohydrate
metabolism status or diabetes duration.
Most importantly, adjusted data conﬁrm
that CD34 cells decrease from NGT to
IGT with a ﬁrst nadir in newly diagnosed
patients. The partial recovery of progenitor
cellsduringthesubsequent20yearshasnot
a clear explanation. Antihyperglycemic
treatment, either with lifestyle or pharma-
cological interventions, might have had
beneﬁcial effects on progenitor cells. Ad-
justment for treatment should minimize
this bias, but we could not control for cu-
mulative exposure to antihyperglycemic
drugs. Moreover, physical exercise, which
canstimulateprogenitorcellsandisusually
encouraged soon after diabetes diagnosis,
may account in part for the observed cell
values. To rule out that the development of
CVD-stimulated repeated bursts of progen-
itor cell mobilization due to subclinical ep-
isodes of ischemia, we excluded patients
with acute CVD and controlled for chronic
CVD in model 1.
Interestingly, variation of CD34
KDR cells, which can be equated to EPCs
(23), was somehow similar to CD34 cell
variation (supplemental Fig. 1). We found a
trend toward early EPC reduction in newly
diagnosed type 2 diabetes and another dip in
longer-lasting disease. However, ﬂuctua-
tions in CD34KDR levels were much
morepronounced,andthegapbetweenob-
served and adjusted values was larger and
more inconsistent than for CD34 cells.
This might reﬂect that endothelial-primed
progenitors are more susceptible to the
changing patient phenotype and cumula-
tive therapeutic intervention than generic
progenitor cells.
This is the ﬁrst study thoroughly de-
scribing trends of progenitor cells during
development and progression of type 2
diabetes, but it has several limitations. Its
cross-sectional nature does not allow to
draw deﬁnite conclusions on progenitor
cell evolution at the single-patient level.
Thelimitednumberofpatientsinsomeof
the groups may account for an apparently
inconsistent trend, while CIs of adjusted
values are wide because a number of con-
founders had to be controlled for.
Notwithstanding these limitations, we
suggest that our data may have pathophys-
iological implications. Of remarkable inter-
est is the progenitor cell nadir in newly
diagnosed type 2 diabetic patients. To dig
deeper into this pathologic observation, we
exploredsomemechanismsofCD34pro-
genitor cell reduction, such as the effects of
drugs, the role of VEGF, bone marrow
mobilization, and apoptotic cell death.
We found that none of the known
EPC-modulating treatments were cross-
sectionally associated with different
CD34cellcounts.VEGFappearedtoplay
minor or no role in the variation of progen-
itor cell counts from NGT to pre-diabetes
and overt diabetes, and no correlation be-
tween VEGF and cell counts was found.
Conversely, we found that the lower the
count of CD34 cells the higher their apo-
ptotic rate, indicating that apoptosis occur-
ring in the bloodstream might reduce
progenitorcelllevel.However,therewasno
difference in the apoptotic rate between di-
abeticpatientsandthosewithNGT,andthe
percentage of CD34 cell apoptosis was
too low (usually 10%) to explain a 40%
decreaseincellcount,suggestingthatother
mechanismsareoperating.Inprinciple,any
peripheral cause of progenitor cell reduc-
tion (e.g., apoptosis) should be normally
compensatedbybonemarrowmobilization
to restore the peripheral blood progenitor
cell pool. Thus, in the presence of a steady-
state reduction of circulating progenitors, a
functional bone marrow defect can be pos-
tulated. By showing a close direct correla-
tion between peripheral blood and bone
marrow CD34 cells and a low bone mar-
row cell content in diabetic versus nondia-
betic patients, we support the hypothesis of
a bone marrow defect in diabetes. This is in
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tion of a defective postischemic bone mar-
row mobilization in experimental diabetes
(24) and with recent ﬁndings showing that
a speciﬁc form of bone marrow neuropathy
accounts for reduced circulating progeni-
tors in a rat type 2 diabetic model (25).
Therefore, we hypothesize that worsening
glucosemetabolisminIGTandnewlydiag-
nosed diabetes progressively induces a sort
of bone marrow “stunning,” leading to the
early progenitor cell nadir. Subsequent
bonemarrowadaptationorreducedcellap-
optosismightexplainapartialrecovery,de-
spite the development of concomitant risk
factors and CVD. Interestingly, after 20
years of disease, a deeper nadir takes place
that is poorly inﬂuenced by confounding
factors, possibly suggesting an exhaustion
of bone marrow adaptation capacity and
functional reserve.
At present, there are many drugs able
to increase circulating progenitor cells,
including statins, ACE inhibitors, and gli-
tazones, which are commonly used in di-
abetic patients (4,21). Given that CD34
progenitor cell reduction predicts cardio-
vascular events beyond classical risk fac-
tors (6,14), we may be persuaded to
aggressively treat patients in the early
phasesafterdiagnosisoftype2diabetesin
order to preserve marrow function longer
and to prevent CVD.
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